Aspilets/Aspilets-EC Drug Interactions

Angiotensin-converting enzyme (ACE) inhibitors: Hyponatremic and hypotensive effects of ACE inhibitors may be diminished.
Acetazolamide: Increased serum acetazolamide concentrations and toxicity due to competition at the renal tubule for secretion.
Anticoagulant therapy (Heparin, Warfarin): Increased risk of bleeding because of drug-drug interactions and the effect on platelets.
Anticonvulsants: Salicylate can displace protein-bound phenytoin and valproic acid, leading to decreased total concentration of phenytoin and increased serum valproic acid levels.
Beta-blockers: Diminished hypotensive effects of beta-blockers due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.
Diuretics: Diminished effectiveness of diuretics in patients with underlying renal or cardiovascular disease due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention.
Methotrexate: Salicylate may inhibit renal clearance of methotrexate, leading to bone marrow toxicity, especially in the elderly or renal impaired.
NSAIDs: Increased bleeding or may lead to decreased renal function.
Oral hypoglycemics: Moderate doses of aspirin may increase the effectiveness of oral hypoglycemic drugs, leading to hypoglycemia.
Uricosuric agents (Probenecid, Sulfinpyrazone): Salicylates antagonize the uricosuric action of these agents.